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Abstract
Background: Resection is the cornerstone of curative treatment for many non-
metastatic gastric cancers (GCs), but the population treatment patterns remains
largely unknown. This large international population-based study aimed at
investigating the treatment patterns and trends for nonmetastatic GC in Europe
and the United States and at exploring factors associated with resection.
Methods: Data of patients with microscopically confirmed primary inva-
sive GC without distant metastasis from the national cancer registries of the
Netherlands, Belgium, Sweden, Norway, Slovenia, and Estonia and the US
Surveillance, Epidemiology, and End Results (SEER)-18 Programwere retrieved.
Age-standardized treatment rates were computed and trends were evaluated
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using linear regression. Associations of resection with patient and tumor char-
acteristics were analyzed using multivariable-adjusted log-binomial regression.
Analysis was performed in each country respectively without pooling.
Results:Together 65 707 nonmetastaticGCpatients diagnosed in 2003-2016were
analyzed. Age-standardized resection rates significantly decreased over years in
all countries (by 4-24%). In 2013-2014, rates varied greatly from 54 to 75%. Patients
with increasing ages, cardia cancers, or cancers invading adjacent structure were
significantly less frequently resected. Resection was further associated with sex,
performance status, comorbidities, tumor histology, tumor size, hospital type,
and hospital volume. Association patterns and strengths varied across countries.
After multivariable adjustment, resection rates remained decreasing (prevalence
ratio = 0.97-0.995 per year), with decreasing trends consistently seen in various
subgroups.
Conclusions: Nonmetastatic GCs were less frequently resected in Europe and
the United States in the early 21st century. Resection rates varied greatly across
countries and appeared not to be optimal. Various factors associated with resec-
tion were revealed. Our findings can help to identify differences and possibly
modifiable places in clinical practice and provide important novel references for
designing effective population-based GC management strategies.
∙ In Europe and the United States, nonmetastatic gastric cancers were less fre-
quently resected in the early 21st century.
∙ Resection rates varied greatly across countries and appeared not optimal.
∙ Various factors associated with resection were revealed.
∙ Our findings identify differences and possibly modifiable places in clini-
cal practice and provide important novel references for designing effective
population-based management strategies.
KEYWORDS
gastric cancer, international population-based study, patterns, policymaking and resource allo-
cation, resection, trends, variation
1 BACKGROUND
Worldwide approximately 1 034 000 patients are esti-
mated to be newly diagnosed with gastric cancer (GC) and
approximately 783 000 GC-associated deaths are estimated
to occur in 2018, making it the fifth most commonly diag-
nosed malignancy and the third leading cause of cancer-
related mortality.1 The majority of patients with early-
stage GCs can be cured, however, in Western countries
many GC patients have advanced diseases at diagnosis.2
Adequate resection remains the cornerstone of potentially
curative treatment which can assure long-term survival for
medically fit patients with resectable nonmetastatic GC.3–5
Notably, involvement of peristomach structures in non-
metastatic cancers might preclude resection.
GC is marked for the global variations in etiology,
incidence, patient and tumor characteristics, manage-
ment, and outcomes.6,7 Being less prevalent, GC care has
not been well investigated in Western countries, which
potentially hampers survival improvement. Real-worldGC
treatment patterns at the population level, which may
be directly associated with the overall survival statistics,
have remained largely unknown in most Western coun-
tries except the Netherlands.8,9 Notably, the application of
resection, which is the fundamental treatment for GC, has
been rarely studied. International analyses of treatment
patterns and trends could help to identify differences and
possibly modifiable patterns in clinical practice, of poten-
tial relevance for guiding adequate health policymaking
and resource allocation.
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In this large international population-based study, we
investigated the application of resection for nonmetastatic
GCs in Europe and the United States and explored the fac-
tors associated with resection.
2 METHODS
2.1 Patients
An extensive retrieval of nationwide population-based reg-
istries was performed, and the selection of contacted Euro-
pean registries is shown in Supporting information Table
S1. Individual-level data of GC patients from national
population-based cancer registries of the Netherlands, Bel-
gium, Sweden, Norway, Slovenia, and Estonia, and the
US Surveillance, Epidemiology, and End Results (SEER)-
18 Program were finally included (Table 1).The SEER Pro-
gram is an authoritative source for cancer statistics in
the United States, and currently collects data on cancer
incidence and survival from population-based cancer reg-
istries covering approximately 35% of the US population.10
Registry characteristics have been described in detail
previously,11 and the data were generally of high quality.
This study was approved by the Ethics Committee of the
Medical Faculty Heidelberg.
Cancer topography and morphology followed the
International Classification of Diseases for Oncology,
Third Edition.12 Only patients with microscopically con-
firmed primary invasive malignancies of the stomach
(C16) registered in 2003 through 2017 were selected.
To focus on patients who may have potentially cura-
tive resections and for whom those resections would
make a considerable difference to outcomes, analyses
were restricted to cancers without distant metastasis.
Both cardia and noncardia GCs were included. Indi-
viduals with noninvasive benign/premalignant/in situ
tumors, non-GC neoplasms, involving the stomach, gas-
trointestinal stromal tumors/sarcomas, neuroendocrine
tumors/carcinoids, lymphomas, or germ-cell neoplasms,
were excluded (Supporting information Table S2). Cases
diagnosed based on death certificate only (DCO)/autopsy
were also excluded.
Data on patient (year of diagnosis, sex, and age), cancer
(location, differentiation, histology, and stage), treat-
ment (resection, chemotherapy, and radiotherapy), and
follow-up variables (survival time and status) (re)coded
following a uniform data-request sheet were obtained.
Information on hospital type (the Netherlands, Belgium,
and Sweden), hospital volume (the Netherlands, Bel-
gium (for resected patients only), and Sweden), tumor
size (the US), Eastern Cooperative Oncology Group
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Sweden), American Society of Anesthesiologists (ASA)
score (Sweden), and comorbidities (Eindhoven, the
Netherlands and Belgium) were only available in certain
registries.
Resection was defined as removal of the primary tumor
irrespective of the type, extent, and radicality of exci-
sion and lymphadenectomy, and of the method, approach,
procedure, and technique of management, and included
open, minimally invasive, and endoscopic (only used for a
small proportion of cancers with invasion limited to lam-
ina propria/submucosa) resection. Tumor local invasion,
lymph node involvement, and distant metastasis were
derived from the American Joint Committee on Cancer
(AJCC)/Union for International Cancer Control (UICC)
TNM staging, and were reclassified into categories consis-
tent across the investigated period when the sixth/seventh
edition was in effect.
2.2 Statistics
Data were analyzed and presented separately in each
country without pooling. Patient age was categorized into
four groups (<60, 60-69, 70-79, and ≥80 years). Age-
standardized treatment rates were calculated using the
age distribution of the US patients, the largest group of
patients analyzed, as the standard. Temporal trends of
the standardized rates were assessed using linear regres-
sion, and rates over two-calendar-year periods were shown
graphically. Subgroup analyses according to patient age
and tumor location were further conducted, and age- and
location-specific rates in 2010 or later were graphically
illustrated.
Multivariable log-binomial regression models were
constructed to investigate the associations of resection
with patient and tumor characteristics with adjustment
for year of diagnosis, sex, age group, tumor location,
and histology in main analyses. Log-binomial maximum
likelihood prevalence ratios (PRs) were computed.13 Sub-
group analyses according to age, location, histology, and
invasion of adjacent structures were further conducted.
Further sensitivity analyses were performed by limiting
patients to those with tumor invasion beyond submucosa
and/or with positive lymph nodes where endoscopic
resection was rarely performed. Associations with addi-
tional variables (adjacent structure invasion, hospital
type and volume, tumor size, ECOG-PS and ASA scores,
and comorbidities) were evaluated by adding them one
by one into the main models in countries with available
information. SAS software (v.9.4; Cary, NC) was used for
analyses. Statistical significance was defined by two-sided
P < .05.
3 RESULTS
Overall 1 33 321 GC patients registered in the population-
based registries were initially included (Table 1). Patients
with DCO/autopsy-based diagnosis (1%), without micro-
scopically confirmed or eligible pathology (11%), with non-
invasive diseases (1%), without information on distant
metastasis status (8%), and with distant metastasis (30%)
were excluded. Exclusion of patientswith unknownmetas-
tasis status affected overall resection rates by only 0-3%
units in the United States, the Netherlands, Sweden, Nor-
way, and Slovenia, but markedly increased the resection
rate in Belgium (from 51 to 61%), where the proportion of
unknown metastasis was relatively high (22%; Supporting
information Table S3). Finally 65 707 patients with non-
metastatic disease were analyzed. Characteristics of over-
all and resected nonmetastatic GC patients are shown in
Table 2 and detailed in Supplementary Results.
3.1 Resection trends
Age-standardized resection rates decreased over time in
all countries (Figure 1). The largest average decreases
were observed in Norway (2003-2004 to 2013-2014: 78 to
54%; Ptrend < .001) and Sweden (2005-2006 to 2013-2014: 69
to 54%; Ptrend < .001). Moderate decreases were observed
in the United States (2003-2004 to 2013-2014: 72 to 60%;
Ptrend < .001) and Estonia (2009-2010 to 2013-2014: 80 to
74%; Ptrend = .020). The Netherlands (2005-2006 to 2013-
2014: 72 to 68%; Ptrend = .005), Belgium (2003-2004 to 2013-
2014: 80 to 75%; Ptrend < .001), and Slovenia (2003-2004 to
2013-2014: 77 to 70%; Ptrend = .002) showed the slightest
decreases.
When limiting cancers to those without adjacent struc-
ture invasion and to those invading beyond submucosa
and/or with positive lymph nodes where endoscopic resec-
tion was rarely performed, the decreasing resection trends
remained in all countries.
3.2 Resection trends according
to age group and tumor location for
nonmetastatic cancers
Subgroup analyses of resection trends according to
age group and tumor location were further conducted
(Figure 2). Resection rates were higher in younger
patients, and the decreasing trends were weaker or
disappeared in patients <70 years compared to those
≥70 years in the Netherlands (2005-2006 to 2013-2014: 83
to 83%, Ptrend = .915 vs 63 to 54%, Ptrend < .001), Sweden



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































USA The Netherlands Belgium Sweden Norway Slovenia Estonia
F IGURE 1 Age-standardized resection rates for nonmetastatic gastric cancers. In the United States and Norway, the decreasing trends
started from as early as the 1980s and the 1960s, respectively (data not shown)
citatsatem-non ,aidrac-noNcitatsatem-non ,aidraC
































































































USA The Netherlands Belgium Sweden Norway Slovenia Estonia
F IGURE 2 Age-standardized resection rates for nonmetastatic gastric cancer by age and tumor location
(2005-2006 to 2013-2014: 80 to 66%, Ptrend = .011 vs.60 to
43%, Ptrend < .001), and Slovenia (2003-2004 to 2013-2014:
84 to 84%, Ptrend = .807 vs 71 to 58%, Ptrend = .002). The
decreasing trends were stronger in patients <70 years in
Norway (2003-2004 to 2013-2014: 90 to 60%, Ptrend < .001
vs 68 to 48%, Ptrend = .001), and Estonia (2009-2010 to 2013-
2014: 89 to 80%, Ptrend = .011 vs.72 to 68%, Ptrend = .149). The
magnitudes of decrease were similar in both age groups in
















































Gastric cardia Gastric fundus/body Gastric antrum/pylorus Other
F IGURE 3 Resection rates for nonmetastatic gastric cancers by age group and tumor location in 2010 or later
Belgium (2003-2004 to 2013-2014: 86 to 80%, Ptrend = .010
vs.75 to 70%, Ptrend < .001).
Resection rates for cardia cancers were lower than those
for noncardia tumors. The magnitude of decrease was
weaker in cardia cancers than noncardia ones in Sweden
(2005-2006 to 2013-2014: 63 to 56%, Ptrend = .008 vs 75 to
56%, Ptrend < .001). The trendswere only significant in non-
cardia cancers in Belgium (2003-2004 to 2013-2014: 82 to
78%; Ptrend = .016), Slovenia (2003-2004 to 2013-2014: 90 to
82%; Ptrend = .006), and Estonia (2009-2010 to 2013-2014:
82 to 75%; Ptrend = .035). Similar decreasing magnitudes in
cardia and noncardia cancers were observed in the United
States (2003-2004 to 2013-2014: 64 to 54%, Ptrend < .001 vs78
to 69%, Ptrend < .001), the Netherlands (2005-2006 to 2013-
2014: 66 to 58%, Ptrend < .001 vs 78 to 73%, Ptrend = .016), and
Norway (2003-2004 to 2013-2014: 67 to 46%, Ptrend = .001 vs
85 to 65%, Ptrend < .001).
3.3 Recent resection rates for GC by age
group and tumor location
We limited the patients to those diagnosed in 2010 or
later, a recent period when all countries had data, to
calculate the resection rates according to age group and
tumor location (Figure 3). Resection rates decreased with
increasing ages in all countries. The rates were markedly
lower in patients ≥80 years (27% [Sweden] to 66% [Esto-
nia]) compared to the other age groups (<60 years: 65%
[Norway] to 88% [Slovenia]; 60-69 years: 63% [Norway]
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to 87% [Slovenia]; 70-79 years: 55% [Sweden] to 79%
[Belgium]), with large variations across countries. In most
countries, resection rates were lower for cardia cancers
(49% [Sweden] to 74% [Belgium]) than for fundus/body
(54% [Sweden] to 88% [Slovenia]) or pylorus/antrum
cancers (58% [Sweden] to 81% [Slovenia]).
3.4 Factors associated with resection
We further investigated variables associated with resection
in each country using multivariable-adjusted log-binomial
models (Table 3), which further supported the decreasing
resection rates (PR per year = 0.97 [Sweden, Norway, and
Estonia] to 0.995 [the Netherlands] across countries).
While resection was not significantly associated with
sex, it was less frequently performed with older age and
for cardia cancer in all countries. Specifically, compared to
patients<60 years, PRs for resection in patients aged 70-79
and ≥80 years were 0.86 (the Netherlands) to 0.95 (Nor-
way) and 0.49 (Sweden) to 0.79 (Estonia), respectively. In
all countries except Estonia where associations with loca-
tion were insignificant, resection rates of fundus/body and
antrum/pylorus cancers were higher than those of cardia
cancers, with PRs ranging from 1.06 (Belgium) to 1.21 (Nor-
way) and from 1.11 (Belgium) to 1.34 (Norway), respectively.
Resection was less often conducted for signet ring cell car-
cinomas (SRCs) in the United States. Adjacent structure
invasion was associated with less frequent resection in all
countries (PR = 0.57 [Sweden] to 0.80 [Norway]).
Associations of resectionwith further variables available
in certain countries are shown in Table 4. Management
in academic hospitals was associated with more frequent
resection in the Netherlands, Belgium, and Sweden. In
the Netherlands and Sweden, a smaller hospital volume
was associated with less frequent resection. In the United
States, resection was more frequently performed for
smaller tumors. With higher ECOG-PS and ASA scores,
resection was much less often performed. Cardiac disease,
vascular disease, and pulmonary disease were associated
with less frequent resection. More than two comorbidi-
ties were associated with 9% reduced resection rates in
Eindhoven. The decreasing resection trends over time
remained after adjusting for these factors.
3.5 Subgroup analyses regarding the
association of resection with year of
diagnosis
Subgroup analyses on the association of resection with
year of diagnosis were performed according to age, tumor
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TABLE 4 Association of hospital type, hospital volume, tumor size, performance status, and comorbidities with resection in
nonmetastatic gastric cancer in registries with available information using multivariable-adjusted log-binomial regression
The US The Netherlands Belgium Sweden
Variable Category n PR (95% CI)1 N PR (95% CI) n PR (95% CI) n PR (95% CI)
Hospital type Nonacademic – – 7857 1.00 (reference) 3906 1.00 (reference) 2515 1.00 (reference)





<10 – – 1232 0.93 (0.90-0.96) – – 872 0.92 (0.87-0.96)
10-20 – – 1374 0.94 (0.91-0.97) – – 931 0.97 (0.94-1.01)
≥20 – – 1000 1.00 (reference) – – 1373 1.00 (reference)
Tumor size
(cm)
<2 1694 1.04 (1.03-1.05) – – – – – –
2-4 2747 1.02 (1.01-1.03) – – – – – –
≥4 5056 1.00 (reference) – – – – – –
ECOG score 0-1 – – – – 4285 1.00 (reference) 3194 1.00 (reference)
2 – – – – 510 0.87 (0.81-0.93) 763 0.51 (0.45-0.57)
≥3 – – – – 159 0.48 (0.39-0.60) 287 0.15 (0.10-0.22)
ASA score 1-2 – – – – – – 2949 1.00 (reference)
3 – – – – – – 1166 0.74 (0.68-0.79)
≥4 – – – – – – 236 0.31 (0.24-0.42)
Comorbidity Cardiac disease – – 615/1437 0.93 (0.87-1.00) 3405/3063 0.99 (0.96-1.01) – –
Vascular disease – – 349/1703 0.89 (0.81-0.98) – – – –
Hypertension – – 588/1464 1.00 (0.94-1.06) – – – –
Diabetes – – 336/1716 0.94 (0.86-1.02) 980/5488 0.97 (0.93-1.00) – –
Pulmonary
disease
– – 255/1797 0.95 (0.86-1.05) 370/6098 0.94 (0.88-1.00) – –
Comorbidity
no.
0 – – 609 1.00 (reference) – – – –
1 – – 548 1.00 (0.95-1.06) – – – –
≥2 – – 895 0.91 (0.85-0.98) – – – –
1Prevalence ratios and 95% confidence intervals for associations of hospital type, hospital volume, tumor size, ECOG score, ASA score, and comorbidity with resec-
tion versus nonresection were calculated by adding these variables one by one into the main multivariable-adjusted log-binomial regression models adjusting for
year of diagnosis, sex, age group, tumor location, and histology. The reference categories for each comorbidity were those without the corresponding comorbidity.
Previous cancer was available and also adjusted for in the United States, the Netherlands, and Belgium. All models converged. Statistically significant prevalence
ratios are shown in bold. Numbers for comorbidities are shown for with/without the respective comorbidity.
ASA, American Society of Anesthesiologists; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group PR, prevalence ratio; -, not available.
70 years as the age cutoff, considering the findings that
compared to patients aged <60 years, those aged 70-79
and ≥80 years had significantly lower resection rates in
most countries, while the resection rates for those aged 60-
69 years were mostly not significantly different (Table 3),
and that patients aged ≥70 years comprised nearly half
of the total patients (51-62%) (Table 1).While association
patterns in subgroups were mostly similar to the overall
ones, some interesting differences were observed.
Compared to patients <70 years, the decreasing trends
were stronger in those ≥70 years in the United States,
the Netherlands, Sweden, and Slovenia. Compared to non-
cardia cancers, the decreasing trends were stronger for
cardia cancers in the Netherlands and Norway. In SRCs,
in cancers without adjacent structure invasion, and in
cancers invading beyond submucosa or having positive
lymph nodes, association patterns and strengths were
mostly similar with those for total cancers. For cancers
invading adjacent structure, resection rates increased in
the Netherlands and more strongly decreased in Sweden,
and trends became insignificant in Belgium, Norway, and
Slovenia.
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4 DISCUSSION
To our knowledge, this is the largest international
population-based report on patient and tumor character-
istics, treatment trends, and treatment-associated factors
for nonmetastatic GC across Europe and the United States.
Our study revealed large variations in treatment patterns
across countries. Somewhat unexpectedly, resection rates
decreased for nonmetastatic cancers, for which resection
remains the only curative treatment. The decreasing trend
was consistently seen in various subgroups. Furthermore,
several tumor and patient characteristics associated with
resection were revealed.
The observed decreasing trends are consistent with
some previous studies from the United States and the
Netherlands. In the United States during 1983-2002, resec-
tion rates declined by 6% units in all stages, and by
even 20% units in local stages.14,15 Using the US Nation-
wide Inpatient Sample in 1988-2000, gastric resection rate
showed a 20% decline.16 In theNetherlands, resection rates
for stage I-III noncardia cancer decreased from 71% in 1989-
1992 to 62% in 2005-2008, while rates for cardia cancer
remained relatively stable during that period.9 Resection
trends in the other European countries have been rarely
reported.
In Western countries, there is consensus that medi-
cally fit patients with nonmetastatic resectable GC should
undergo standardized resection in specialized, high-
volume centers.17–19 While GC surgery has shown some
trends of centralization, the degree and the initiation
time vary across countries. We found that proportions
of patients managed and of resections performed in aca-
demic hospitals increased moderately in the Netherlands
(2005-2014: 14-22% and 17-34%) and Belgium (2004-2013:
38-43% and 40-47%), and strongly in Sweden (2006-2016:
34-70% and 38-84%). In the United States, proportions of
gastrectomyperformed at centerswith≥9 yearly resections
increased from 43% in 1988-1989 to 48% in 1999-2000.16 We
found that the proportions of patients managed (27-29%)
and of resections performed (33-33%) in hospitals with
≥20 annual gastric/esophageal resections remained rela-
tively stable during 2005-2014 in the Netherlands, where
centralization of GC surgery has essentially been imposed
since 2012 only.20,21 Proportions of resections done in hos-
pitals with ≥20 yearly resections increased moderately in
Belgium (2004-2013: 18-28%). In Sweden, proportions of
patients treated (30-72%) and of resections (32-68%) per-
formed in hospitals with ≥20 yearly resections increased
strongly in 2006-2016.
We found that GC was most commonly diagnosed in
patients ≥70 years and at stomach cardia. For elderly
patients who are more commonly frail the resection-
upfront approach might be suboptimal unless specifi-
cally tailored.22 Geriatric assessment would be helpful
before initiating treatment for older patients. However, GC
patients were getting increasingly younger in the inves-
tigated period. Cardia cancer may be more surgically
challenging.23 While the recently increasing incidence of
cardia cancer potentially impedes resection,5,24 resection
rates for noncardia cancer were also decreasing. Cancers
invading adjacent structures had lower R0 resection rates,
which potentially bars resection. The different patterns
and strengths of associations of resection with patient and
tumor characteristics across countries highlight the varia-
tion in clinical practice and the need for standardization.
We have observed increasing clear-margin (R0) resec-
tion rates among all resections for nonmetastatic can-
cer in the Netherlands (2005-2014: 83-88%) and Sweden
(2006-2016: 83-92%). Furthermore, proportions of resec-
tions with ≥15 examined lymph nodes for nonmetastatic
disease increased in the United States (2004-2014: 36-51%),
the Netherlands (2005-2014: 32-67%), and Sweden (2006-
2016: 42-82%). While these trends could partly reflect the
surgical advances, they might also indicate the increas-
ingly stricter selection criteria of resection candidates.
While resection rates decreased, the indicated higher suc-
cess rates and better quality of resection could contribute
to better results for resected patients.
Following the pivotal MAGIC trial (2006),25 periopera-
tive therapy is recommended as standard of care for most
resectable GC planned for resection throughout many
parts of Europe, and is increasingly favored over adjuvant
treatment.25–28 While the preoperative approach might
enhance resectability by down-staging tumor, it also allows
substantial time for further growth of advanced cancers or
metastases, which potentially impeded the application of
resection. Greater access to and wider use of chemother-
apy and/or radiotherapy and presurgical chemotherapy-
associated toxicity might also preclude some patients from
receiving further resection.29,30
Proper patient selection for treatment is paramount.
Physician recommendation and expertise, and patient
preference and adherence importantly impact treatment
choice. In patients with unresected nonmetastatic GC in
SEER-18, the proportion of those recommended for surgery
decreased from 12% in 2004 to 11% in 2014. The aggres-
sive nature of GC and historically poor outcomes even in
the setting of operable disease should be discussed with
patients before treatment. Patient nutrition and psychoso-
cial statuses, organ function, medical history, tolerability,
therapeutic burden especially cost, potential benefit from
resection, postoperativemorbidity andmortality, and qual-
ity of life should also be factored into treatment decisions.
This study was limited by its observational nature.
Some variables were not recorded in certain countries,
and the quality of registration might vary. Endoscopic
HUANG et al. 13 of 15
resection was recorded and clearly differentiated from
surgical resection only in the Netherlands and Sweden. To
maintain the consistency of definition and analysis across
countries, the term “resection” rather than “surgery” was
used in our study. Endoscopic resection is in essence a type
of and belongs to resection, like the case of surgical resection.
Sensitivity analyses by limiting patients to those who are
clearly not appropriate candidates for endoscopic resection
revealed similar trends. While variables included in the
main models were complete, some variables were not
included in modeling due to the relatively high propor-
tions of missing values (e.g., differentiation). Proportions
of unknown metastasis were particularly high in Belgium
(22%) compared to the other countries (4-10%). We did
not pool or compare data between countries, considering
the potential heterogeneity, but analyzed, presented,
and interpreted data for each country separately. It is
noteworthy that the proportion of cardia cancer was very
low in Slovenia (27%) and Estonia (12%), and SRC was
very often diagnosed in Estonia (28%). While this could
be partly explained by differences in dietary and obesity
patterns and the prevalence of Helicobacter pylori infec-
tion, potential variation in clinical and registry practice
might also play a role which underlines the importance
of further standardization. The reasons for the observed
decreasing resection trends were not totally clear. Further
studies are needed to explore factors accounting for the
observed decreasing resection rates. The investigated
time periods were not totally identical. Nevertheless, they
mostly covered the period 2003/2004-2013/2014, and year
of diagnosis was adjusted for in all multivariable models.
Finally, our analyses were restricted to the United States
and European countries, and the results may not be gen-
eralized to other parts of the world, especially countries in
East Asia where the incidence rates of GC are high.
Notably, the largest sample size ever investigated, uni-
formly defined variables across nationwide population-
based registries from multiple countries, careful case
selection and quality control, and standardized statistical
methods enabled this report to show important infor-
mative results regarding treatment for GC that warrants
clinicians’ and policymakers’ great attention.
In conclusion, nonmetastatic GCs were less frequently
resected in Europe and the United States in the early
21st century. Resection rates varied greatly across coun-
tries, and appeared not to be optimal. Various variables
associated with resection were revealed. Our findings
can help to identify differences and possibly modifiable
places in clinical practice and provide important novel
references for designing effective population-based GC
management strategies, of potential important relevance
for guiding adequate health policymaking and resource
allocation.
ACKNOWLEDGMENTS
This study was partly supported by the German Cancer
Aid (Deutsche Krebshilfe, #111365). The funder had no
involvement in study design; in the collection, analysis,
or interpretation of data; in the writing of the report; or in
the decision to submit the paper for publication.
We are very grateful to the European Registration of
Cancer Care (EURECCA) group for their great support
and to the staff in Surveillance, Epidemiology, and End
Results Program (SEER), Netherlands Cancer Registry
(NCR), Belgian Cancer Registry (BCR), Swedish Cancer
Registry (SCR), Cancer Registry of Norway (CRN), Cancer
Registry of Slovenia (CRS), and Estonian Cancer Registry
(ECR) for their kind work in data collection and delivery.
Open access funding enabled and organized by Projekt
DEAL.
[Correction added on 7November 2020, after first online
publication: Projekt Deal funding statement has been
added].
AUTH ORS ’ CONTRIBUT IONS
Guarantor of the article: Hermann Brenner, MD, MPH.
Conception or design: Huang L, Jansen L, Schrotz-King P,
and Brenner H.
Acquisition, analysis, or interpretation of data: Huang
L, Jansen L, Balavarca Y, VerhoevenR, Ruurda J, Van Eyck-
enL, De SchutterH, Johasson J, LindbladM, Johannesen T,
Zadnik V, Zagar T, Mägi M, Bastiaannet E, Lagarde S, van
de Velde C, Schrotz-King P, and Brenner H. Drafting of the
manuscript: Huang L. Critical revision of the manuscript
for important intellectual content: Jansen L, Balavarca Y,
VerhoevenR,Ruurda J, VanEyckenL,De SchutterH, Johas-
son J, Lindblad M, Johannesen T, Zadnik V, Zagar T, Mägi
M, Bastiaannet E, Lagarde S, van de Velde C, Schrotz-
King P, Brenner H. Statistical analysis: Huang L, Balavarca
Y. Administrative, technical, or material support: van de
Velde C and Brenner H.
All authors have given final approval of the manuscript
for submission and publication.
ETH ICS APPROVAL
This study was approved by the Ethics Committee of the
Medical Faculty Heidelberg. Consent was not obtained for
this observational, population-based, and registry-based
study. The presented secondary data are anonymous with-
out any risk of identification, and no individual patient
data were reported.
AVAILAB IL ITY OF DATA AND
MATERIAL
The Surveillance, Epidemiology, and End Results (SEER)
Program data are available upon reasonable request and
14 of 15 HUANG et al.
with permission of the registry. The other data that support
the findings of this study are available fromeach participat-
ing registry but restrictions apply to the availability of these
data, which were used under license for the current study,
and so are not publicly available.
CONFL ICT OF INTEREST




1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statis-
tics 2018: gLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
2018;68(6):394-424. https://doi.org/10.3322/caac.21492.
2. Thrumurthy SG, Chaudry MA, Hochhauser D, et al. The diag-
nosis and management of gastric cancer. BMJ. 2013;347:f6367.
https://doi.org/10.1136/bmj.f6367.
3. Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment
of gastric cancer: 15-year follow-up results of the randomised
nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439-449.
https://doi.org/10.1016/S1470-2045(10)70070-X.
4. Ajani JA, D’Amico TA, Almhanna K, et al. Gastric cancer, ver-
sion 3.2016, NCCN clinical practice guidelines in oncology. J
Natl Compr Canc Netw. 2016;14(10):1286-1312.
5. Smyth EC, Verheij M, Allum W, et al. Gastric cancer: eSMO
Clinical Practice Guidelines for diagnosis, treatment and follow-
up. Ann Oncol. 2016;27(suppl 5):v38-v49. https://doi.org/10.
1093/annonc/mdw350.
6. Strong VE, Song KY, Park CH, et al. Comparison of gas-
tric cancer survival following R0 resection in the United
States and Korea using an internationally validated nomo-
gram. Ann Surg. 2010;251(4):640-646. https://doi.org/10.1097/
SLA.0b013e3181d3d29b.
7. Ferro A, Peleteiro B, Malvezzi M, et al. Worldwide trends in
gastric cancer mortality (1980-2011), with predictions to 2015,
and incidence by subtype. Eur J Cancer. 2014;50(7):1330-1344.
https://doi.org/10.1016/j.ejca.2014.01.029.
8. Nelen SD, van Putten M, Lemmens V, et al. Effect of age on
rates of palliative surgery and chemotherapy use in patients
with locally advanced or metastatic gastric cancer. Br J Surg.
2017;104(13):1837-1846. https://doi.org/10.1002/bjs.10621.
9. Dassen AE, Dikken JL, van de Velde CJ, et al. Changes in
treatment patterns and their influence on long-term survival in
patients with stages I-III gastric cancer in The Netherlands. Int J
Cancer. 2013;133(8):1859-1866. https://doi.org/10.1002/ijc.28192.
10. SEER. Surveillance, Epidemiology, and End Results (SEER)
Program Research Data (1973-2016), National Cancer Insti-
tute, DCCPS, Surveillance Research Program, released April
2019, based on the November 2018 submission. 2019. www.seer.
cancer.gov (accessed May 30th, 2018).
11. Huang L, Jansen L, Balavarca Y, et al. Resection of pancreatic
cancer in Europe and USA: an international large-scale study
highlighting large variations. Gut. 2019;68(1):130-139. https://
doi.org/10.1136/gutjnl-2017-314828.
12. WHO. International Classification of Diseases for Oncology, 3rd
edn. 2018. http://codes.iarc.fr/ (accessed January 30th, 2018).
13. Spiegelman D, Hertzmark E. Easy SAS calculations for
risk or prevalence ratios and differences. Am J Epidemiol.
2005;162(3):199-200. https://doi.org/10.1093/aje/kwi188.
14. McGhan LJ, Etzioni DA, Gray RJ, et al. Underuse of cura-
tive surgery for early stage upper gastrointestinal cancers in
the UnitedStates. J Surg Res. 2012;177(1):55-62. https://doi.org/
10.1016/j.jss.2012.03.013.
15. Le A, Berger D, Lau M, et al. Secular trends in the use, quality,
and outcomes of gastrectomy for noncardia gastric cancer in the
UnitedStates. Ann Surg Oncol. 2007;14(9):2519-2527. https://doi.
org/10.1245/s10434-007-9386-8.
16. Wainess RM, Dimick JB. Epidemiology of surgically treated
gastric cancer in the UnitedStates, 1988–2000. J Gastroin-
test Surg. 2003;7(7):879-883. https://doi.org/10.1007/s11605-003-
0033-9.
17. Dikken JL, van Sandick JW,AllumWH, et al. Differences in out-
comes of oesophageal and gastric cancer surgery across Europe.
Br J Surg. 2013;100(1):83-94. https://doi.org/10.1002/bjs.8966.
18. Begg CB, Cramer LD, Hoskins WJ, et al. Impact of hospital vol-
ume on operative mortality for major cancer surgery. JAMA.
1998;280(20):1747-1751.
19. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital
volume and surgical mortality in the UnitedStates. N Engl
J Med. 2002;346(15):1128-1137. https://doi.org/10.1056/NEJMsa
012337.
20. Busweiler LA, Wijnhoven BP, van Berge HenegouwenMI, et al.
Early outcomes from the Dutch Upper Gastrointestinal Cancer
Audit. Br J Surg. 2016;103(13):1855-1863. https://doi.org/10.1002/
bjs.10303.
21. van Putten M, Verhoeven RH, van Sandick JW, et al. Hospi-
tal of diagnosis and probability of having surgical treatment for
resectable gastric cancer. Br J Surg. 2016;103(3):233-241. https:
//doi.org/10.1002/bjs.10054.
22. Cunningham D, Chua YJ. East meets west in the treatment of
gastric cancer. N Engl J Med. 2007;357(18):1863-1865. https://doi.
org/10.1056/NEJMe078182.
23. Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdomi-
nal approach versus abdominal-transhiatal approach for gastric
cancer of the cardia or subcardia: a randomised controlled trial.
Lancet Oncol. 2006;7(8):644-651. https://doi.org/10.1016/S1470-
2045(06)70766-5.
24. Colquhoun A, Arnold M, Ferlay J, et al. Global patterns
of cardia and non-cardia gastric cancer incidence in 2012.
Gut. 2015;64(12):1881-1888. https://doi.org/10.1136/gutjnl-2014-
308915.
25. Cunningham D, Allum WH, Stenning SP, et al. Periopera-
tive chemotherapy versus surgery alone for resectable gastroe-
sophageal cancer. N Engl J Med. 2006;355(1):11-20. https://doi.
org/10.1056/NEJMoa055531.
26. Cunningham D, Starling N, Rao S, et al. Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N Engl J Med.
2008;358(1):36-46. https://doi.org/10.1056/NEJMoa073149.
27. Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly
fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)
for patients with metastatic adenocarcinoma of the stom-
ach or esophagogastric junction: a phase II trial of the
HUANG et al. 15 of 15
ArbeitsgemeinschaftInternistischeOnkologie. Ann Oncol.
2008;19(11):1882-1887. https://doi.org/10.1093/annonc/mdn403.
28. YchouM, Boige V, Pignon JP, et al. Perioperative chemotherapy
compared with surgery alone for resectable gastroesophageal
adenocarcinoma: an FNCLCC and FFCD multicenter phase III
trial. J Clin Oncol. 2011;29(13):1715-1721. https://doi.org/10.1200/
JCO.2010.33.0597.
29. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison
of preoperative chemotherapy compared with chemoradiother-
apy in patients with locally advanced adenocarcinoma of the
esophagogastric junction. J ClinOncol. 2009;27(6):851-856. https:
//doi.org/10.1200/JCO.2008.17.0506.
30. Macdonald JS. Treatment of localized gastric cancer. Semin
Oncol. 2004;31(4):566-573.
SUPPORT ING INFORMATION
Additional supporting information may be found online
in the Supporting Information section at the end of the
article.
How to cite this article: Huang L, Jansen L,
Balavarca Y, et al. Decreasing resection rates for
nonmetastatic gastric cancer in Europe and the
United States. Clin Transl Med. 2020;10:1–15.
https://doi.org/10.1002/ctm2.203
